MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:32Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:SGLT2 inhibitors]]
			[[Category:Antihyperglycemic agents]]
			[[Category:Heart failure medications]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #92

2026-05-23T03:42:10Z

parser-claude batch MedTemplate pre-fill, Top 300 #92

New page

{{MedTemplate
| generic = Dapagliflozin
| brand = Farxiga (US), Forxiga (international)
| structure =
| classes = [[:Category:SGLT2_inhibitors|SGLT2 inhibitor]], [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]], [[:Category:Heart_failure_medications|Heart failure medication]]
| uses = <vote slug="type2-diabetes-use">Type 2 diabetes mellitus</vote>, <vote slug="hfref-use">Heart failure with reduced ejection fraction</vote>, <vote slug="hfpef-use">Heart failure with preserved ejection fraction</vote>, <vote slug="ckd-use">Chronic kidney disease</vote>
| starting_dose = 10 mg PO once daily in the morning; 5 mg starting in heart failure
| preparations = 5 mg, 10 mg tablets
| fda_max = 10 mg/d
| pill_id =
| routes = Oral
| onset = Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months
| duration = 24 hours
| halflife = ~12.9 hours<ref name="farxiga-label">FDA Prescribing Information, Farxiga (dapagliflozin), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s029lbl.pdf</ref>
| bioavailability = ~78% (oral; high-fat meal modestly reduces but is not clinically significant)<ref name="farxiga-label" />
| pregnancy = Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="dapagliflozin-mech-claim">Dapagliflozin selectively inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubule, blocking ~50-60% of filtered glucose reabsorption and producing dose-dependent glycosuria, natriuresis, and mild osmotic diuresis independent of insulin action.</vote> Cardiovascular and renal benefits (DAPA-HF, DAPA-CKD, DELIVER) substantially exceed what HbA1c lowering predicts and are attributed to combined effects on preload, blood pressure, intraglomerular pressure via tubuloglomerular feedback, and likely metabolic/inflammatory mechanisms<ref name="farxiga-label" />. Genital mycotic infections, euglycemic DKA (especially with insulin reduction or fasting), and rare Fournier's gangrene are the characteristic class adverse effects.
}}

== References ==
<references />

Dapagliflozin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #92